AEON Biopharma (AEON) Change in Account Payables (2022 - 2025)

AEON Biopharma has reported Change in Account Payables for 4 years, with the latest figure at -$1.6 million in Q4 2025.

• Quarterly Change in Account Payables fell 223.67% year-over-year to -$1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$5.0 million (down 77.81% YoY) and the FY2025 annual result came in at -$5.0 million, down 296.99% from the prior year.
• Change in Account Payables declined to -$1.6 million in Q4 2025 per AEON's latest filing, from -$1.4 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $5.2 million in Q4 2022 and troughed at -$3.7 million in Q3 2023.
• A 4-year average of -$610600.0 and a median of -$1.5 million in 2025 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2024 and 2025: Change in Account Payables surged 188.99% in 2024, then sank 223.67% in 2025.
• Over 4 years, Change in Account Payables stood at $5.2 million in 2022, then tumbled by 171.74% to -$3.7 million in 2023, then jumped by 134.45% to $1.3 million in 2024, then tumbled by 223.67% to -$1.6 million in 2025.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$1.6 million, -$1.4 million, and $1.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.